Barclays’s AbbVie ABBV Stock Holding History

Barclays’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.21B	Buy	5,571,610 +731,465	+15%	+$162M	0.29%	46
2025 Q4	$1.11B	Sell	4,840,145 -53,279	-1%	-$12.1M	0.27%	51
2025 Q3	$1.13B	Buy	4,893,424 +39,492	+0.8%	+$8.04M	0.25%	51
2025 Q2	$901M	Sell	4,853,932 -735,334	-13%	-$137M	0.21%	57
2025 Q1	$1.17B	Buy	5,589,266 +2,729,067	+95%	+$531M	0.33%	35
2024 Q4	$508M	Sell	2,860,199 -1,975,042	-41%	-$363M	0.14%	89
2024 Q3	$955M	Buy	4,835,241 +454,595	+10%	+$84.8M	0.25%	45
2024 Q2	$751M	Buy	4,380,646 +585,387	+15%	+$97M	0.23%	60
2024 Q1	$691M	Buy	3,795,259 +532,338	+16%	+$91.7M	0.24%	74
2023 Q4	$506M	Sell	3,262,921 -560,400	-15%	-$81.7M	0.19%	89
2023 Q3	$570M	Sell	3,823,321 -205,961	-5%	-$30.2M	0.35%	52
2023 Q2	$543M	Buy	4,029,282 +2,079,578	+107%	+$305M	0.34%	55
2023 Q1	$311M	Sell	1,949,704 -1,538,083	-44%	-$235M	0.14%	85
2022 Q4	$564M	Buy	3,487,787 +720,738	+26%	+$111M	0.25%	50
2022 Q3	$371M	Buy	2,767,049 +984,585	+55%	+$141M	0.41%	41
2022 Q2	$273M	Sell	1,782,464 -981,234	-36%	-$150M	0.17%	84
2022 Q1	$448M	Sell	2,763,698 -1,450,419	-34%	-$211M	0.35%	53
2021 Q4	$571M	Buy	4,214,117 +339,670	+9%	+$40.1M	0.21%	89
2021 Q3	$418M	Buy	3,874,447 +935,964	+32%	+$107M	0.19%	84
2021 Q2	$331M	Buy	2,938,483 +678,807	+30%	+$76.4M	0.16%	99
2021 Q1	$245M	Sell	2,259,676 -297,379	-12%	-$31.8M	0.13%	123
2020 Q4	$274M	Sell	2,557,055 -2,354,041	-48%	-$226M	0.14%	105
2020 Q3	$430M	Buy	4,911,096 +2,966,779	+153%	+$279M	0.26%	57
2020 Q2	$191M	Sell	1,944,317 -257,799	-12%	-$22.7M	0.15%	108
2020 Q1	$168M	Sell	2,202,116 -982,024	-31%	-$83.6M	0.13%	108
2019 Q4	$282M	Buy	3,184,140 +627,388	+25%	+$52.1M	0.16%	108
2019 Q3	$194M	Sell	2,556,752 -589,451	-19%	-$40.4M	0.12%	126
2019 Q2	$229M	Buy	3,146,203 +175,509	+6%	+$13.8M	0.14%	114
2019 Q1	$239M	Sell	2,970,694 -203,369	-6%	-$16.6M	0.17%	89
2018 Q4	$293M	Sell	3,174,063 -2,142,557	-40%	-$188M	0.23%	65
2018 Q3	$503M	Buy	5,316,620 +1,464,592	+38%	+$139M	0.35%	35
2018 Q2	$357M	Buy	3,852,028 +321,933	+9%	+$31.4M	0.31%	48
2018 Q1	$334M	Buy	3,530,095 +782,425	+28%	+$86M	0.26%	72
2017 Q4	$266M	Buy	2,747,670 +1,352,790	+97%	+$127M	0.22%	81
2017 Q3	$124M	Sell	1,394,880 -46,139	-3%	-$3.51M	0.13%	129
2017 Q2	$104M	Sell	1,441,019 -41,550	-3%	-$2.79M	0.11%	134
2017 Q1	$96.6M	Buy	1,482,569 +332,431	+29%	+$20.9M	0.11%	143
2016 Q4	$72M	Buy	1,150,138 +209,598	+22%	+$12.8M	0.08%	200
2016 Q3	$59.3M	Sell	940,540 -265,909	-22%	-$17.2M	0.07%	220
2016 Q2	$74.7M	Buy	1,206,449 +97,761	+9%	+$5.96M	0.1%	169
2016 Q1	$63.2M	Buy	1,108,688 +24,649	+2%	+$1.37M	0.1%	166
2015 Q4	$64M	Sell	1,084,039 -336,345	-24%	-$19.4M	0.08%	216
2015 Q3	$76.7M	Sell	1,420,384 -1,004,902	-41%	-$65.4M	0.09%	186
2015 Q2	$162M	Sell	2,425,286 -1,849,822	-43%	-$121M	0.18%	78
2015 Q1	$248M	Buy	4,275,108 +522,248	+14%	+$31.6M	0.29%	44
2014 Q4	$244M	Sell	3,752,860 -1,324,370	-26%	-$83.5M	0.23%	61
2014 Q3	$289M	Buy	5,077,230 +3,305,662	+187%	+$184M	0.28%	43
2014 Q2	$99.2M	Sell	1,771,568 -547,588	-24%	-$28.7M	0.1%	151
2014 Q1	$118M	Sell	2,319,156 -48,248	-2%	-$2.44M	0.13%	125
2013 Q4	$123M	Buy	2,367,404 +108,039	+5%	+$5.31M	0.13%	121
2013 Q3	$99.4M	Buy	2,259,365 +154,758	+7%	+$6.86M	0.12%	118
2013 Q2	$87M	Buy	+2,104,607	New	+$92M	0.11%	135

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barclays's ABBV Position: Q1 2026 in Review

Barclays increased its AbbVie (ABBV) stake by 15% in Q1 2026, buying an estimated $162M and bringing the position to 5,571,610 shares worth $1.21B. The position accounts for 0.29% of the portfolio, ranked #46.

Barclays first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Barclays held 5,571,610 shares of AbbVie worth $1.21B as of Q1 2026.
Barclays bought 731,465 AbbVie shares in Q1 2026, an estimated $162M.
AbbVie made up 0.29% of Barclays's portfolio in Q1 2026, its #46 holding.
Barclays first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.